Reflecting current understanding of the complexities of sexual activity among persons with chronic mental illness, the text draws upon the collective wisdom and experience of experts from a variety of settings. Clinicians, advocates, consumers, researchers, legal experts, and administrators all contribute to document the concerns about sexual behavior and the consequent health risks for this at-risk population. The research presented here is particularly timely in view of recent emphases on patient choice, recovery, and advocacy, and can be used to provide guidance to clinicians, mental health administrators, policymakers, advocates, and researchers.

Schizophrenia is often associated with an inadequate response to pharmacological and non-pharmacological treatments. How to treat patients who have an unsatisfactory response to anti-psychotics, including clozapine - which is unequivocally the most powerful antipsychotic medication for this recalcitrant population - remains a clinical conundrum. A range of adjunctive medications have been tried with mixed results; there has also been renewed interest in the role of neuromodulatory strategies, electroconvulsive therapy, and cognitive and vocational approaches. Perhaps a bright spot for the future lies in the evolution of pharmacogenetic approaches for individualized care. In this book, leading experts from Europe, Australia and the Americas provide a timely appraisal of treatments for the most severely ill schizophrenia patients. This clinically focused book is informed by the latest research on the neurobiology and treatment of schizophrenia. It is comprehensive in scope, covering current treatment options, various add-on approaches, and a range of psychosocial treatments. The contributors are respected experts who have combined their clinical experience with cutting-edge research to provide readers with authoritative information on fundamental aspects of clinical care for schizophrenia.

Psychiatric comorbidities such as depression, anxiety and substance use are extremely common amongst people with schizophrenia. They add to poor clinical outcomes and disability, yet are often not at the forefront of the minds of clinicians, who tend to concentrate on assessing and treating the core symptoms of schizophrenia, notably delusions and hallucinations. There is an imperative to assess every patient with schizophrenia for psychiatric comorbidities, as they might masquerade as core psychotic symptoms and also because they warrant treatment in their own right. This volume addresses these issues using a clinical lens informed by the current literature. Published as part of the Oxford Psychiatry Library series, the book serves as a concise and practical reference for busy clinicians.

Physical health and mental health are inextricably linked together. Moreover, as the biology of mental illnesses is gradually - and inexorably - being elucidated, the overlap between physical illnesses and mental illnesses has become even more apparent. These observations 'set the stage' for readers of this issue of Psychiatric Clinics in which a variety of articles are presented from all aspects of medicine - from emergency mental health to how burn patients heal and cope with the physical and mental outcomes, to coverage of issues such as prolonged stay in the intensive care unit, comorbidities in the elderly, food allergies, depression and other common primary care conditions, and childhood diabetes. A primer on interviewing techniques and role play is presented along with the role of nurses who cross both mental and physical aspects of healthcare and the essential role of a supportive family to the interdiscipinary team .

Part of the Oxford Psychiatry Library of pocketbooks, this user-friendly and practical guide will outline the diagnosis, evaluation and treatment of patients with schizophrenia. Co-authored by two global experts on the management of patients with psychosis, this pocketbook will serve as a useful guide for psychiatrists, trainees, psychiatric specialist nurses, and interested general practitioners. Schizophrenia is one of the most disabling mental illnesses and is also highly prevalent, occurring in approximately 1% of the population and affecting both men and women equally. The disorder has a typical onset of between 15 and 35 years of age and is characterised by impairments in reality, most commonly hallucinations and delusions. It is a highly complex condition and is often confused with other mental disorders such as bipolar disorder. This new edition will cover new DSM-5 diagnostic criteria and to reflect new data and include new longitudinal studies on psychiatric and medical co-morbidity, Genetic and environmental factors, new drug therapies, adherence and the role of depots, new advances in psychosocial therapies (CBT,ACT, & cognitive remediation) and includes an updated and expanded appendix.

Schizophrenia is often associated with an inadequate response to pharmacological and non-pharmacological treatments. How to treat patients who have an unsatisfactory response to anti-psychotics, including clozapine - which is unequivocally the most powerful antipsychotic medication for this recalcitrant population - remains a clinical conundrum. A range of adjunctive medications have been tried with mixed results; there has also been renewed interest in the role of neuromodulatory strategies, electroconvulsive therapy, and cognitive and vocational approaches. Perhaps a bright spot for the future lies in the evolution of pharmacogenetic approaches for individualized care. In this book, leading experts from Europe, Australia and the Americas provide a timely appraisal of treatments for the most severely ill schizophrenia patients. This clinically focused book is informed by the latest research on the neurobiology and treatment of schizophrenia. It is comprehensive in scope, covering current treatment options, various add-on approaches, and a range of psychosocial treatments. The contributors are respected experts who have combined their clinical experience with cutting-edge research to provide readers with authoritative information on fundamental aspects of clinical care for schizophrenia.

Patients' failure to complete a simple prescription course presents a tremendous public health problem and a considerable challenge for practicing clinicians. For those with chronic mental illnesses, non-adherence is an even greater problem than in other patient populations and substantially lowers the possibility of improvement or recovery. Additionally, adherence to treatment is further undermined by impairments in insight that often accompany mental illness. Much has been written about non-adherence across medical specialties. Yet, the topic of non-adherence in psychiatric patients is so common and complex that it merits review in its own right.
Using the most up-to-date research available, this book summarizes the current knowledge concerning non-adherence in mental illness, presenting concise, practical information on such topics as the reasons behind medication non-adherence, detection of non-adherence, and the pharmacological and non-pharmacological options available to clinicians to manage non-adherence. The authors review the effectiveness of psycho-education, brief counseling, compliance therapy, cognitive adaptive strategies, reminder electronic monitoring strategies, family therapy, peer support and recovery, and assertive community treatment (ACT), as well as assess the legal issues around patient adherence, including outpatient commitment and Kendra's law.
Importantly, the text also addresses the ever evolving role of psychiatrists in managing adherence, focusing on the rapid advances in pharmacology, in light of the new and broadening recovery concept for mental illness. The data is presented in a "ready-to-use" manner, utilizing algorithms, diagrams, tables, and figures to convey helpful information to clinicians in order to improve all aspects of psychiatric patient adherence.

The Year Book of Psychiatry and Applied Mental Health brings you abstracts of the articles that reported the year's breakthrough developments in psychiatry and mental health, carefully selected from more than 300 journals worldwide. Expert commentaries evaluate the clinical importance of each article and discuss its application to your practice. There's no faster or easier way to stay informed! Annual topics feature the latest information on biological psychiatry, alcohol and substance-related disorders, psychiatry and the law, psychotherapy, and clinical psychiatry.

Schizophrenia remains a poorly understood and yet a profoundly serious condition among all the major medical illnesses. A major shift in the past 5 years has been witnessed among psychiatrists with the belief now that diagnosis and intervention early may have a positive influence on the outcome of schizophrenia. This shift has led to searching for key diagnostic clusters to enhance early diagnosis as well as to concerted efforts to find biomarkers of disease and disease progression. To that end, this issue of the Psychiatric Clinics of North America is dedicated to these contemporary issues that promote 'early intervention' in schizophrenia. Distinguished academic clinicians and neuroscientists provide comprehensive overviews of the present state of knowledge on the epidemiology, early clinical characteristics, and diagnostic changes, proposed pathogenesis, neurobiology, and treatment requirements for this disorder. The optimism and excitement for real progress in schizophrenia research treatment is incorporated into this text. The current state of knowledge is substantial, academically credible, and scientifically based. Topics on the subject of early intervention in and diagnosis of schizophrenia include: The Nosology of Schizophrenia: Defining Illness Boundaries Based upon Symptoms; The Neurodevelopmental Hypothesis of Schizophrenia: a Critical Synthesis; Predicting Risk and the Emergence of Schizophrenia; Is Early Intervention for Psychosis Feasible and Effective?; Can Neuroimaging Be Used to Define Phenotypes and Course of Schizophrenia?; Reliable Biomarkers and Predictors of Schizophrenia and Its Treatment; From Study to Practice: Enhancing Clinical Trials Methods Toward 'Real World' Outcomes; Relapse Prevention in Schizophrenia; Antipsychotic Polypharmacy: Every Clinician's 'Dirty Little Secret'; Cognitive Remediation: Retraining the Brain in Schizophrenia; Peers and Peer-led Interventions; Homelessness; and The Emerging Role of Technology and Social Media in Caring for People with Schizophrenia. Each presentation in this publication includes an Overview, Implications for Practice, with Summarizations of Important Clinical and Learning Points.

In comparison to the general population, people with schizophrenia and related disorders have poorer physical health and increased mortality. Whilst it is recognised that serious mental illnesses such as schizophrenia carry a reduced life expectancy, it is often assumed that suicide is the main cause of this disparity. In actuality, suicide accounts for no more than a third of the early mortality associated with schizophrenia: the vast majority is due to cardiovascular factors Physical Health and Schizophrenia offers a user-friendly guide to the physical health problems associated with schizophrenia and a clear overview of strategies and interventions to tackle these issues. Spanning eight chapters this resource covers the essential topics in a practical and easy-to-read format to suit the needs of busy clinicians. It also includes an appendix designed specifically for patients and carers, with practical tips on how to be actively involved in monitoring and managing physical health problems. Part of the Oxford Psychiatry Library series, Physical Health and Schizophrenia offers readers a fully up-to-date and valuable insight into this complex issue. With helpful key points at the start of each chapter and a clear layout, this is an essential resource for busy clinicians and researchers in any mental health field as well as those working in primary care.

This issue of the Psychiatric Clinics, edited by Dr. Peter F. Buckley, examines advances and current management in the treatment of Schizophrenia. The topics covered in this issue include, but are not limited to: Duration of Untreated Psychosis (DUP) and Longitudinal Perspectives on DUP; Neuroinflammation and Schizophrenia; Emerging Treatments for Schizophrenia; Treatment-Resistant Schizophrenia; Comorbidities and Schizophrenia; Recovery from Schizophrenia; and the latest in schizophrenia research.